39 completed, 2 terminated, 1 unknown. 27 Phase 2, 16 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 27 | Completed 25, Terminated 1, Unknown 1 |
| Phase 1 | 16 | Completed 14, Terminated 2 |
Follow bryostatin 1: new trials by email Literature Review of bryostatin 1 trials Research Report on bryostatin 1
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety of Bryostatin in Patients With MS Bryostatin 1 - Multiple Sclerosis | Phase 1 | Terminated | Robert Fox | 4 | 2024-06-26 | 2026-03-31 |
| Bryostatin Treatment of Moderately Severe Alzheimer's Disease Bryostatin 1, Placebo - Alzheimer Disease | Phase 2 | Completed | Neurotrope Bioscience, Inc. | 122 | 2020-08-30 | 2024-07-31 |
| A Study Assessing Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer's Disease Bryostatin 1, Placebo - Alzheimer's Disease | Phase 2 | Completed | Neurotrope Bioscience, Inc. | 147 | 2015-11-01 | 2018-07-06 |
| Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment Placebo, Bryostatin 1 (10ug/m2), Bryostatin 1 (20ug/m2) - HIV Infection | Phase 1 | Completed | Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal | 12 | 2014-09-01 | 2015-12-18 |
| Study to Evaluate the Preliminary Safety, Efficacy, PK and PD of Bryostatin 1 in Patients With Alzheimer's Disease Bryostatin 1, Placebo - Alzheimer's Disease | Phase 1 / Phase 2 | Terminated | Neurotrope Bioscience, Inc. | 9 | 2014-06-01 | 2017-11-06 |
| Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics Study of Bryostatin 1 in Patients With Alzheimer's Disease Bryostatin for Injection, Placebo - Alzheimer's Disease | Phase 2 | Unknown | Blanchette Rockefeller Neurosciences Insitute | 9 | 2008-04-01 | 2008-02-01 |
| Temsirolimus and Bryostatin 1 in Treating Patients With Unresectable or Metastatic Solid Tumors bryostatin 1, temsirolimus - Recurrent Melanoma, Recurrent Renal Cell Cancer | Phase 1 | Completed | National Cancer Institute (NCI) | 24 | 2005-03-01 | 2013-05-03 |
| Bryostatin 1 and Rituximab in Treating Patients With B-Cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia rituximab, bryostatin 1 - Leukemia, Lymphoma | Phase 2 | Completed | National Institute on Aging (NIA) | 48 | 2004-07-01 | 2015-04-30 |
| Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin's Lymphoma After Bone Marrow or Stem Cell Transplantation bryostatin 1, vincristine sulfate, laboratory biomarker analysis - Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma | Phase 2 | Completed | National Cancer Institute (NCI) | 28 | 2003-03-01 | 2013-01-10 |
| Paclitaxel and Bryostatin 1 in Treating Patients With Advanced Pancreatic Cancer paclitaxel, bryostatin 1 - Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas | Phase 2 | Completed | National Cancer Institute (NCI) | 19 | 2002-03-01 | 2021-06-11 |
| Interleukin-2 and Bryostatin 1 in Treating Patients With Advanced Kidney Cancer aldesleukin, bryostatin 1, laboratory biomarker analysis - Recurrent Renal Cell Cancer, Stage III Renal Cell Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 65 | 2002-01-01 | 2013-01-24 |
| Bryostatin 1 Plus Vincristine in Treating Patients With Recurrent or Refractory HIV-Related Lymphoma bryostatin 1, vincristine sulfate - AIDS-related Diffuse Large Cell Lymphoma, AIDS-related Diffuse Mixed Cell Lymphoma | Phase 1 | Completed | National Cancer Institute (NCI) | 12 | 2001-11-01 | 2013-01-25 |
| Bryostatin 1 and Cytarabine in Treating Patients With Relapsed Acute Myelogenous Leukemia bryostatin 1, cytarabine - Leukemia | Phase 2 | Completed | Virginia Commonwealth University | 2001-07-01 | 2010-03-01 | |
| Chemotherapy Plus Sargramostim in Treating Patients With Refractory Myeloid Cancer bryostatin 1, sargramostim, laboratory biomarker analysis - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities | Phase 1 | Completed | National Cancer Institute (NCI) | 35 | 2001-03-01 | 2013-01-09 |
| Bryostatin 1 and Cisplatin in Treating Patients With Advanced Recurrent or Residual Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer bryostatin 1, cisplatin, laboratory biomarker analysis - Fallopian Tube Cancer, Primary Peritoneal Cavity Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 32 | 2000-10-01 | 2013-08-26 |
| Bryostatin 1 and Cisplatin in Treating Patients With Metastatic or Unresectable Stomach Cancer bryostatin 1, cisplatin, laboratory biomarker analysis - Stage III Gastric Cancer, Stage IV Gastric Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 12 | 2000-10-01 | 2014-10-01 |
| Interleukin-2 Plus Bryostatin 1 in Treating Patients With Melanoma or Kidney Cancer aldesleukin, bryostatin 1 - Kidney Cancer, Melanoma (Skin) | Phase 1 | Completed | Virginia Commonwealth University | 17 | 2000-09-01 | 2015-12-14 |
| Bryostatin-1 Plus Cisplatin in Treating Patients With Recurrent or Advanced Cancer of the Cervix bryostatin 1, cisplatin - Cervical Cancer | Phase 2 | Completed | Icahn School of Medicine at Mount Sinai | 2000-08-01 | 2013-07-10 | |
| Paclitaxel and Bryostatin 1 in Treating Patients With Metastatic Prostate Cancer bryostatin 1, paclitaxel - Prostate Cancer | Phase 2 | Completed | University of Maryland, Baltimore | 46 | 2000-05-01 | 2019-11-04 |
| Bryostatin 1 Plus Gemcitabine in Treating Patients With Advanced Cancer bryostatin 1, gemcitabine hydrochloride - Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Completed | Barbara Ann Karmanos Cancer Institute | 36 | 2000-05-01 | 2014-04-24 |
Showing 20 of 42. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (8) · Leukemia (7) · Lymphoma (7) · Lymphoma, Follicular (7) · Lymphoma, Non-Hodgkin (7) · Lymphoma, B-Cell, Marginal Zone (6) · Lymphoma, Mantle-Cell (6) · Carcinoma, Renal Cell (5) · Lymphoma, Large B-Cell, Diffuse (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Alzheimer Disease (4) · Burkitt Lymphoma (4) · Leukemia, Myeloid, Acute (4) · Lymphoma, Large-Cell, Immunoblastic (4) · Kidney Neoplasms (3)
National Cancer Institute (NCI) (11) · Barbara Ann Karmanos Cancer Institute (7) · Virginia Commonwealth University (4) · Memorial Sloan Kettering Cancer Center (3) · Neurotrope Bioscience, Inc. (3) · National Institute on Aging (NIA) (2) · Blanchette Rockefeller Neurosciences Insitute (1) · Cancer Research UK (1) · Dana-Farber Cancer Institute (1) · Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal (1) · Icahn School of Medicine at Mount Sinai (1) · Lombardi Comprehensive Cancer Center (1) · NYU Langone Health (1) · Robert Fox (1) · University of Chicago (1)
United States (39) · United Kingdom (2) · Spain (1)
Ayad M. Al-Katib, MD, FACP (4) · Steven Grant, MD (3) · Brenda Cooper (2) · Gary K. Schwartz, MD (2) · Igor Espinoza-Delgado, MD (2) · Philip A. Philip, MD, PhD, FRCP (2) · Adrian L. Harris, MD (1) · Andreas Kaubisch (1) · Andrew S. Kraft, MD (1) · Ann M. Mauer, MD (1) · Arif Hussain, MD (1) · B. Smith (1) · David G. Pfister, MD (1) · David S. Eilender, MD (1) · Farr R. Nezhat, MD (1)
PMID 12581572, PMID 15047228, PMID 17020988, PMID 17145828, PMID 18270704, PMID 19221754, PMID 19738452, PMID 26891037
P30CA022453 (7), P30CA016059 (4), N01CM17101 (2), U01CA062502 (2), N01CM17102 (1), N01CM17103 (1), P01CA015396 (1), R44AG066366 (1), U01CA070019 (1)